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Background: Helicobacter pylori is the main risk-factor for gastric cancer through a cascade
from gastritis through atrophic gastritis (AG), intestinal metaplasia (IM), dysplasia (DYS)
to malignancy. The presence of these lesions in the general population predicts the gastric
cancer incidence in the coming decades. Prevalence data are mostly obtained from serolog-
ical studies and endoscopy data in symptomatic patients.
Aim: To investigate the prevalence of H. pylori infection and its related gastric changes in
asymptomatic subjects.
Methods: 383 Patients undergoing routine colonoscopy were included. All subjects under-
went upper GI endoscopy and completed the Gastrointestinal Symptom Rating Scale
(GSRS). Biopsies were taken from antrum and corpus.
Results: H. pylori infection was present in 22%. Non-Caucasian subjects had a significantly
higher H. pylori prevalence (p < 0.001). AG, IM and DYS were together found in 9.3% of sub-
jects. Subjects with AG, IM or DYS were significantly older (p < 0.001). No differences were
found with respect to gender, presence of GI symptoms as scored by GSRS, lifestyle and
medication use.
Conclusions: The prevalence of premalignant gastric lesions is considerable in general Wes-
tern population with increasing age as the main risk factor. One time screening for prema-
lignant lesions at the age of 60 years is a reasonable strategy since the numbers found
imply that gastric cancer will remain a prevalent disease.
 2010 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Gastric cancer represents the fourth most common malig-
nancy and second leading cause of cancer-related mortality42.
l (C.M. den Hoed).
terology and Hepatology,
y, Saint Lucas Andreas H
terology and Hepatology,
the Elsevier OA license.worldwide. Its worldwide incidence is increasing due to
expansion and ageing of the world population.1–3 In The
Netherlands as in many Western countries, the incidence of
gastric cancer is relatively low with approximately 6.9 cases/Kennemer Gasthuis, Haarlem, The Netherlands.
ospital, Amsterdam, The Netherlands.
University Medical Center Utrecht, Utrecht, The Netherlands.
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the main risk factor for gastric cancer. It is one of the most
common infections in humans with a prevalence in many
developing countries arising to more than 90% in young
adults, and a prevalence in the developed world varying be-
tween 30% and 50%.5,6 H. pylori causes gastritis in virtually
all infected patients, which can lead to atrophic gastritis
(AG), intestinal metaplasia (IM), dysplasia (DYS) and eventu-
ally invasive cancer.7,8 The identification of these precursor
lesions may assist in timely diagnosis of gastric carcinoma
and consequently a better prognosis. A previous study
showed that around 7000 patients in The Netherlands are
diagnosed with one of these gastric precursor lesions every
year.9
These data are relevant for the determination of future
developments in the incidence of gastric cancer and the po-
tential impact of screening. However, they are based on
symptomatic patients referred for upper gastrointestinal
endoscopy. Since most patients with H. pylori infection and
premalignant gastric lesions are asymptomatic, one may as-
sume that a large proportion of these lesions remain unde-
tected. Data on the epidemiology of premalignant gastric
lesions in the general population are thus scarce, especially
in populations with an overall low incidence of gastric can-
cer.9–11 Available data are either based on serology testing or
on used information obtained from patients with an indica-
tion for upper gastrointestinal endoscopy.12,13 A recent popu-
lation-based study from Germany reported a prevalence of
serologically diagnosed atrophic gastritis of 5% in the age
group from 50 to 54 years, increasing to 9% in the age group
of 70–74 years.14 This may have been an underestimate, as
serological assessment of atrophic gastritis has suboptimal
predictive values for mild to moderate degrees of atrophy,
even more so in populations with lower prevalence of the
condition.15
The prevalences of H. pylori gastritis and its sequelae
amongst asymptomatic subjects are not clear. Studies that
use random samples of the general population and histology
to diagnose premalignant lesions mostly contain small num-
bers of patients and are rarely conducted in low incidence
populations.16,17 Adequate data are required for public health
discussions on the potential benefits of screening and treat-
ment for H. pylori infection.
The objective of this study, therefore, was to obtain histo-
logical assessed data on the age-related prevalence of H. pylori
infection and its related macroscopic and pathologic gastric
changes in subjects without an indication for upper gastro-
intestinal endoscopy.2. Methods
Participants for this study were recruited from the list of pa-
tients planned for routine, non-urgent colonoscopy in the
Erasmus Medical Center in Rotterdam, The Netherlands. At
least 2 weeks prior to endoscopy, all candidateswere sent a re-
ply-card letter explaining the aim, background and methods
of the study. The patients were asked to return the reply-card
if they werewilling to be enrolled in the study or wished to re-
ceive further information. The patient’s referring physiciansalso received a letter. Only the patients who returned the re-
ply-card were then contacted by the investigators by phone.
After informed consent, they were prepared for upper gastro-
intestinal endoscopy to take place under midazolam sedation
prior to the colonoscopy in the same session.
All patients entering the study were asked to complete the
Gastrointestinal Symptom Rating Scale (GSRS) prior to the
endoscopic examination. The GSRS measures 15 specific gas-
trointestinal symptoms, using a Likert scale graded from
1 = no discomfort to 7 = very severe discomfort, and depicts
five symptom dimensions (reflux, indigestion, constipation,
diarrhoea and abdominal pain). Progressive scores indicate
increasing symptom levels. TheGSRS iswell documentedwith
regard to reliability and validity in adults with dyspepsia.18
For each subject demographical and lifestyle characteris-
tics were collected together with information about medica-
tion use. Exclusion criteria were a previous or present
history of oesophageal or gastric carcinoma, previous surgery
to the upper gastrointestinal tract as well as an upper gastro-
intestinal endoscopy in the 6 months prior to the colonos-
copy. The study was reviewed and approved by the Erasmus
MC institutional review board.
2.1. Endoscopy
Upper gastrointestinal endoscopy and biopsy sampling were
performed with an Olympus GIF-XP160 endoscope prior to
colonoscopy. Before the start of the procedure local anaes-
thetic spray was applied orally (Xylocaine 10%) and sedation
with 5–7.5 mg midazolam was given intravenously. Macro-
scopic appearance of the stomach was assessed. Routine
endoscopic images were made of antrum, corpus and cardia,
any abnormalities and visible lesions were additionally pho-
tographed. Biopsy specimens were obtained for histology
according to the updated Sydney classification from the an-
trum (n = 2) and corpus (n = 2). In addition biopsies were taken
of any visible abnormality or lesion.
2.2. Histology
Biopsy specimenswere fixed in 4% formalin, embedded in par-
affin wax, sectioned (5 lm) on two levels, stainedwith haema-
toxylin–eosin and mounted on glass slides. Sections were
independently reviewed by two expert pathologists, whowere
unaware of the endoscopic and clinical findings. For each sec-
tion, the presence and severity of gastritis and the degree of
neutrophilic infiltration, lamina propria mononuclear infiltra-
tion and glandular atrophy were graded on the Sydney scales
from 0 to 3. Intestinal metaplasia was scored as either absent
or present and confirmed in all cases by evaluation of PAS
staining. The presence of dysplasia was determined using
the standardised definition also used in Barrett’s oesophagus
and classified with the use of the standardised classification
as defined by the Vienna classification.19–21
2.3. Statistical analysis
Categorical data analysis was conducted using the chi-square
or Fisher exact test performed with Statistical Package for the
Social Sciences (SPSS) 15.0. Continuous data were analysed
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between medication use and lifestyle characteristics and gas-
tritis, logistic regression analysis was performed with SPSS.
The level of significance was set at 0.05. All tests were two-
tailed.
3. Results
3.1. Baseline characteristics
A total of 383 patients were included in the study, with a male
to female ratio of 191/192 and a mean age of 53.1 years (range
17–86 years). Their baseline characteristics are described in
Table 1. Most patients were referred to our outpatient clinic
for a colonoscopy because of changes in defecation pattern
(25%), abdominal pain (12%), or suspicion of inflammatory
bowel disease (20%). The majority of the patients were of
Caucasian descent (90%). Forty-three percent of the patientsTable 1 – Baseline characteristics of subjects (N = 383).
Total N %
Male/female 383 191/192 50/50
Age (average) 383 53 (17–86)
Ethnicity 373
Caucasian 336 90
Negroid 21 5.5
Asian 4 1
Other 12 3.4
BMI 368
<20 28 7.6
20–25 171 47
25–30 122 33
30–35 31 8.4
35–40 15 4.1
>40 1 0.3
Smoking 367
None 188 51
Current 91 25
Former 88 24
Alcohol 369
None 143 39
0–2 units/day 176 48
3–5 units/day 41 11
>5 units/day 9 2.4
NSAIDS 371
None 322 87
Sometimes 24 6.5
Often 25 6.7
Aspirin 371
No 330 89
80 mg daily 38 10
38 mg daily 3 0.9
PPI 371
No 293 79
Yes 78 21
GSRS score: 383
Dyspepsia score > 2.5 135 35
Indigestion score > 2.5 87 23
IBS score > 2.5 206 54were current or former smokers, and 63% regularly consumed
alcohol with an average intake of two consumptions daily
(range 1–10). Complaints of dyspepsia as scored in the GSRS
scale were found in 35% of the patients. Protonpump inhibi-
tors were currently used by 20% of the total patient group.
3.2. Endoscopic findings
One-hundred twenty-three (32%; 95% CI [27–37%]) subjects
demonstrated macroscopic evidence of gastric pathology.
Twenty-five percent (n = 95; 95% CI [21–29%]) showed evidence
of gastritis. Erosionswere seen in 5% (n = 20; 95% CI [2.8–7.2%])
of the subjects. The erosions were all located in the antrum.
Two (0.5%; 95% CI [0–1.2%]) subjects had an ulcer, one in the
lesser curvature and one on the angulus. Macroscopic evi-
dence of atrophy was seen in 1.6% (95% CI [0.3–2.8%]). The
prevalence of gastritis and erosions in subjects undergoing a
colonoscopy because of IBD was equal to the subjects referred
for other causes. In the subjects referred for suspected IBD,
20% (95% CI [16–24%]) showed evidence for gastritis and 4%
(95% CI [2.0–5.9%]) for antrum erosions, respectively.
3.3. Histopathological findings
H. pylori infection was demonstrated in 22% (95% CI [18–26%])
of subjects (Fig. 1). Subjects with H. pylori gastritis were signif-
icantly older than subjects with normal gastric mucosa (mean
age 56.1 versus 51.9; 95% CI [0.5–7.3], p 0.03). The prevalence of
H. pylori gastritis increased with age. Eleven percent of sub-
jects under 40 years of age were colonised with H. pylori. This
prevalence rose to a maximum of 33% in subjects 50–60 years
of age (Fig. 2). In the non-Caucasian subjects the prevalence of
H. pylori was 44% overall, ranging from 33% (95% CI [28–38%])
in the subjects under 40 years of age to 57% (95% CI [54–60%])
in those above 50 years (Table 2).
In 11% of the subjects with histopathologically diagnosed
gastritis, no signs of H. pylori were identified, this percentage
decreased to 9.5% when excluding subjects referred for IBD.
Most subjects with H. pylori-negative gastritis demonstrated
signs of foveolar hyperplasia, suggestive for chemical gastritis.
There was no correlation between the presence of H. pylori
gastritis and dyspeptic symptoms. In fact, the Gastrointestinal
Symptom Rating Scale (GSRS) showed an equal proportion of
subjects with dyspeptic symptoms among the gastritis-
negative subjects and the H. pylori-positive subjects (36%;
95%CI [31–40%]) versus (41%; 95%CI [36–46%], p 0.44). Nodiffer-
ences were foundwith respect to smoking behaviour, BMI and
medication use between H. pylori-positive and -negative
subjects (Table 2). However, both groups differed with respect
to alcohol use (H. pylori-positive versus -negative 47%; 95% CI
[42–52%] versus 67%; 95% CI [63–72%], p 0.02). Furthermore,
we found a significantly higher percentage of non-Caucasian
subjects in the H. pylori-positive group compared to the group
of subjects who were H. pylori negative (24%; 95% CI [20–28%]
versus 5.5%; 95% CI [3.2–7.8%], p < 0.01).
3.4. Premalignant gastric lesions
In total, 9.3% (95% CI [6.4–12%]) of subjects had signs of pre-
malignant gastric lesions; 0.8% had the most severe diagnosis
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Fig. 1 – Prevalence of H. pylori colonization and histopathologic findings.
0
5
10
15
20
25
30
35
<40 40-50 50-60 60-70 >70
n=74 n=86 n=101 n=82 n=40
Age group
Pe
rc
en
ta
ge
HP
PM
Legend: H. pylori  infection (HP), premalignant gastric lesions (PM)  
Fig. 2 – The prevalence of H. pylori infection and premalignant gastric lesions per age.
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metaplasia (IM) and 1.4% in addition had signs of gastric dys-
plasia (DYS).
Subjects with pre-malignant gastric lesions were signifi-
cantly older than subjects with either normal gastric mucosa
or non-atrophic gastritis (mean age 60.0 versus 52.5 years;
95% CI [3.7–11.5], p < 0.01). Premalignant gastric lesions oc-
curred mostly in the subjects over 60. Intestinal metaplasia
and dysplasia were highly prevalent in the higher age groups.
IM was present in 2.3% of the 30–40 years old subjects,
increasing to 13.4% in the age group 60–70 years (Fig. 2). Com-
paring subjects with and without histopathological evidence
of premalignant gastric lesions, no differences were identified
with respect to sex, lifestyle and medication use. Use of pro-
tonpump inhibitors tended to be lower in the group with pre-
malignant gastric lesions, (67%, 95% CI [62–72%] versus 78%,
95% CI [74–82%]), this difference was, however, not significant(p 0.07). The GSRS scores did not have a predictive value for
the presence of premalignant gastric lesions p 0.17 (95% CI
[0.7–3.5]) for positive GSRS score indicating dyspepsia, p 0.35
(95% CI [0.7–3.3]) for positive GSRS score indicating indiges-
tion (Table 2). An association between ethnicity and the
occurrence of premalignant gastric lesions was not demon-
strated (95% CI [0.57–1.58]; p 0.07) (Table 2).
3.5. Correlation of macroscopic and histopathological
findings
Erosions and peptic ulcers were found in 9.5% (95% CI [6.6–
12%]) of subjects with H. pylori compared to 4.7% (95% CI
[2.6–6.8%]) of those without H. pylori infection (p 0.04). Ero-
sions and ulcers were identified in 15% of subjects with
premalignant lesions (95% CI [11–19%]) compared to 4.9%
in subjects without histopathological lesions (95% CI
Table 2 – Characteristics of patients with histopathological evidence of gastritis, H. pylori infection and premalignant gastric
lesions, compared to subjects with unaffected gastric mucosa.
Tot
(N = 383)
PA nl
(N = 226)
Gastr
(N = 95)
p-Value HP
(N = 84)
p-Value PM
(N = 34)
p-Value
Sex male 50% 51% 44% 0.24 44% 0.27 50% 1.0
female 50% 49% 56% 56% 50%
Age (average) 53 53 55 0.12 56 <0.01 60 0.03
Smoking 0.31 0.35 0.20
Never 55% 52% 61% 61% 43%
Current 25% 27% 21% 21% 30%
Former 20% 21% 18% 18% 27%
Alcohol 0.02 0.02 0.14
None 39% 34% 52% 52% 52%
0–2 48% 51% 40% 41% 37%
3–5 11% 13% 5.3% 4.8% 12%
>5 2.4% 2.6% 2.2% 2.4% 0%
Ethnicity <0.01 <0.01 0.07
Caucasian 90% 95% 79% 76% 85%
Negroid 5.5% 2.9% 14% 16% 12%
Asian 1% 0.7% 1.1% 1.2% 3%
Other 3.4% 1.8% 6.6% 7.2% 0%
BMI > 25 46% 44% 49% 0.29 46% 1.0 46% 1.0
NSAIDS 0.64 0.35
None 87% 88% 84% 82% 97% 0.17
Sometimes 6.5% 5.9% 6.5% 9.5% 3%
Often 6.7% 6.3% 6.5% 8.3%
Aspirin 0.58 0.5 0.25
None 89% 87% 90% 92% 82%
80/100 mg 10% 10% 10% 8% 18%
38 mg 0.9% 1.1% 0% 0%
PPI 0.10 0.17 0.07
Yes 79% 78% 84% 84% 67%
No 21% 22% 16% 16% 33%
Ulcera 5.8% 4.7% 9.6% 0.06 9.5% 0.04 14.7% 0.04
GSRS score:
Dyspepsia score > 2.5 35% 36% 40% 0.27 41% 0.44 48% 0.17
Indigestion score > 2.5 23% 62% 58% 0.24 62% 0.89 70% 0.35
IBS score > 2.5 54% 62% 51% 0.06 51% 0.11 59% 1.0
All subjects (Tot), normal gastric mucosa (PA nl), gastritis (Gast), H. pylori infection (HP), premalignant gastric lesions: atrophic gastritis,
intestinal metaplasia or dysplasia (PM).
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raised in six subjects, one of them had histopathological
evidence of intestinal metaplasia, two were diagnosed with
H. pylori infection, and the other three did not have histopa-
thological evidence of gastric pathology.
4. Discussion
Ourknowledgeon theprevalenceofH. pylorigastritis and its se-
quelae of glandular atrophy, intestinal metaplasia, dysplasia
and gastric carcinoma is largely based on studies in symptom-
atic patients referred for upper gastrointestinal endoscopy. For
example, studies from various countries12,13,22,23 reported
H. pylori prevalence rates of 30–41% and the presence of
atrophic gastritis in 7–34%, intestinal metaplasia in approxi-
mately 20% and low grade dysplasia in 1% of patients withdyspeptic symptoms requiring upper GI endoscopy. However,
the patients under study did not represent the general popula-
tion, and thus the reported prevalencesmay have been overes-
timated. This was illustrated by a study from Norway which
showed that symptomatic patients with an indication for
upper GI endoscopy had a significantly lower prevalence of
atrophic gastritis than asymptomatic subjects.17
Comparing our study to a previous nationwide study from
our group, we observed a 9.3% (95% CI [6.4–12%]) prevalence of
premalignant gastric lesions in the current study, compared
to 14% in the previous study by de Vries et al.9 This previous
study included patients with an indication for upper GI
endoscopy and biopsy sampling. This indicates even more
that the numbers obtained from symptomatic patients are
an overestimation of the true population prevalence of pre-
malignant lesions.
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gastric lesions were in particular obtained from serologic
studies.24,25 For example, a recent large study by Weck dem-
onstrated by means of measurements of IgG antibodies for
H. pylori, in combination with pepsinogen I and II and their ra-
tio, a 49% prevalence of H. pylori, and an 8.7% prevalence of
chronic atrophic gastritis in 9444 asymptomatic subjects. A
very recent study from Finland used the same serologic
parameters and demonstrated a H. pylori prevalence rate of
19% and chronic atrophic gastritis in 3.5%.30 However, these
outcomes may have been an underestimate of the true popu-
lation prevalence of atrophic gastritis, as serological assess-
ment of atrophic gastritis has suboptimal predictive values
for mild to moderate degrees of atrophy, even more so in pop-
ulations with lower prevalence of the condition.15 Further-
more, these studies do not clarify the true population
prevalence of intestinal metaplasia and dysplasia, the further
steps in the cascade.
Our results show that there is a marked prevalence of
premalignant gastric conditions in subjects without an indi-
cation for upper GI endoscopy. These lesions vary from
H. pylori-related gastritis to intestinal metaplasia and in
some patients to dysplasia. In this group of subjects without
indication for upper GI endoscopy, macroscopic lesions were
identified in over 30%. The majority of cases had evidence
of gastritis, with erosions, ulcers and atrophy following
other common conditions. With respect to microscopy the
most important finding however, was the considerable prev-
alence of premalignant gastric lesions. In 9.3% of the sub-
jects premalignant gastric lesions were identified, varying
from signs of gland loss to metaplastic replacement and
dysplasia.
In the Swedish Kalixanda study, 16.9% of the subjects were
diagnosed with gastric IM, a prevalence which was twice as
high as in our Dutch population.6 This was likely to be related
to the lower prevalence of H. pylori infection in our subjects
compared to the Kalixanda population. The mean age of our
population and the Kalixanda population was equal (53.07
and 53.5 years) which means that age cannot have contrib-
uted to the difference in prevalence. Other endoscopy studies
that included asymptomatic subjects showed even higher
prevalences of H. pylori infection and premalignant gastric le-
sions.26,27 These studies were, however, conducted either two
or more decades ago or in areas with high H. pylori preva-
lences in the range of 40–75%.26,27
No clear risk factors were identified for the presence of the
premalignant lesions in our subjects. The only factor related
to the presence of premalignant gastric conditions was
increasing age, a factor which has been described previously.
GSRS scores, smoking, use of NSAIDs and BMI could not aid in
identifying the subjects at risk.
In the most previously conducted studies no association
between premalignant gastric lesions and symptoms,
smoking, use of NSAIDs and other medications was
identified.18,25,28,29 Data on potential association between
premalignant lesions and alcohol use are conflicting. We did
not demonstrate such an association.25,28,29 Our subjects were
not selected on the basis of absence of symptoms, or other
parameters such as absence of PPI use, or absence of H. pylori
infection. They thus reflected the general population and theyno one had a clinical indication for upper gastrointestinal
endoscopy.
The H. pylori prevalence of 22% (95% CI [18–26%]) demon-
strated in this study was lower than previously noted in our
population. Overall H. pylori infection rates in The Nether-
lands, determined by serological tests, varied in previous
studies between 35% and 44%.30,31 In a recent survey among
800 healthy blood donors throughout the country, the preva-
lence of H. pylori IgG serum antibodies was 32%. This preva-
lence increased with age from 17% in donors aged
18–28 years to 49% in donors aged 59–70 years.30,31 The lower
prevalence in our study in comparison with previous data
points at a further decline of H. pylori prevalence in The Neth-
erlands. This decline occurs primarily in Caucasian subjects,
the prevalence in non-Caucasian Dutch residents is still high
(>44%). This ethnical diversity in prevalence has also been
demonstrated by other studies.31,32 The same applies to our
observation of increasing prevalence with age.6,17,25,27,33
Despite our efforts to create a risk profile and develop tools
for targeted screening and surveillance, no clear predictors
for the presence of premalignant lesions were found, other
than age and ethnicity. This is in line with previous stud-
ies.31,32 Targeted screening should take these predictors into
account. This, however, implies that a large proportion of
the general population would need to be approached, prefer-
entially with a stepwise strategy starting with serological
testing followed by endoscopy with biopsy sampling in those
with results beyond a set cut-off. Age is the primary determi-
nant in such an approach, with the border set at a level above
which the prevalence of premalignant lesions reaches a
threshold. In our population, the prevalence of premalignant
lesions was 15.9% at the age of 60. This high prevalence is
associated with a rapid increase of gastric cancer incidence
above 60 years. For that purpose, one time screening for pre-
malignant lesions at the age of 60 years is in our Western pop-
ulation a reasonable strategy for which attendance, impact,
costs and optimal approach would have to be determined.
Considering ethnicity and the significantly higher prevalence
of H. pylori infection in non-Caucasian subjects, non-
Caucasian subjects should in such a programme be
approached at a lower age, preferentially aiming at a similar
prevalence of pre-malignant lesions as in Caucasians at the
age of 60 years. In our study, this was reached at the age of
50 years in immigrants. Primary screening should consist of
non-invasive serologic screening, testing for H. pylori antibod-
ies (IgG) and pepsinogen I and II. Ultimately endoscopic
surveillance should be offered to the individuals with prema-
lignant lesions at high risk of progression. For the current
subjects who were actually submitted to screening for prema-
lignant lesions using upper GI endoscopy, endoscopic and
histopathological findings did in some cases have implica-
tions for follow up. There are at present no clear guidelines
on the management of patients with premalignant gastric
lesions. Nevertheless, we previously showed in a large nation-
wide cohort study that this risk is substantial, in particular for
patients with gastric dysplasia.11 The risk of cancer is very
similar to for instance the risk observed in patients with
Barrett’s oesophagus.34 For these reasons, despite the absence
of a management guideline, we offered patients with dyspla-
sia a surveillance upper GI endoscopy within 1–2 years, and
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OLGIM classification35 surveillance within 2–5 years.
Although we included subjects with a clinical indication
for upper GI endoscopy some possible limitations of our study
should be mentioned. All subjects included in this study had
an indication for outpatient colonoscopy, which means that
specific conditions of the GI tract were suspected or had pre-
viously been diagnosed. Special attention in this case was gi-
ven to the group of subjects that had were known or
suspected to have IBD as an indication for their colonoscopy,
since this group of subjects could show some signs of IBD in
the upper GI tract. Our findings, however, did not demon-
strate differences between these subjects and the subjects
with other indications. Especially we did not find a higher
prevalence of ulcerations and gastritis in this group.
Furthermore, our study was conducted in a tertiary centre,
which could have caused selection bias although we are not
aware in which way this would have occurred. The histopa-
thological diagnosis was based on four biopsies; which could
have caused underdiagnosis. Our current biopsy protocol is
more extensive, based on our recent observation that the
optimal biopsy protocol should contain nine random biopsies
(three antrum, one angulus, two corpus and one cardia) for
optimal assessment of the condition of the gastric mucosa.36
Finally, we based our diagnosis of H. pylori infection on histo-
pathology only. Addition of other methods could have
resulted in higher H. pylori prevalences, in particular in
subjects with atrophic gastritis in 90% of whomwe now found
evidence of H. pylori colonisation.6,37,38
Considering histopathological diagnosis of atrophic gastri-
tis and dysplasia it is known that diagnostic criteria may vary
from country to country and inter-observer variability is com-
mon. In the case of atrophic gastritis the updated Sydney sys-
tem does provide clear criteria to score atrophic gastritis and
aides in solving this issue. In the case of dysplasia the diag-
nostic criteria used by our two expert pathologists were:
low-grade dysplastic features, i.e. mild atypia with elongated
nuclei, normal cellular orientation and presence of immature
goblet cells; high-grade dysplasia, i.e. severe atypia with nu-
clear stratification, loss of cellular orientation and lack of gob-
let cell differentiation.
In conclusion we have demonstrated a considerable
prevalence of premalignant gastric lesions, from H. pylori gas-
tritis to high grade dysplasia, in subjects without specific
symptoms. It is especially noteworthy that even severe pre-
malignant lesions can be found in these asymptomatic sub-
jects. Our findings imply that gastric cancer will remain a
common disease in Western countries for the coming two
decades. However, the prevalence of premalignant lesions is
smaller in asymptomatic subjects than in symptomatic pa-
tients. This indicates that data from endoscopy series in
symptomatic subjects do not reflect true population inci-
dences. Finally, we show that only age and ethnicity help to
predict the individual chance of premalignant gastric lesions.
One time screening for premalignant lesions at the age of
60 years seems a reasonable strategy since the numbers
found imply that gastric cancer will remain a prevalent
disease.Conflict of interest statement
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